Sentinel Tablets 230/11.5 11.5 mg Tablet is a Health Canada–registered veterinary drug (DIN 02229548) held by Novartis Animal Health Canada Inc, containing Milbemycin Oxime. Health Canada lists its status as Cancelled Post Market (status date 22 Jun 2000). Nexara Health has matched 10 registrations of Milbemycin Oxime across 1 other regulated market.
Health Canada registration
| DIN | 02229548 |
|---|---|
| Brand name | Sentinel Tablets 230/11.5 |
| Active ingredient | Milbemycin Oxime |
| Strength | 11.5 mg |
| Dosage form | Tablet |
| Route | Oral |
| Company | Novartis Animal Health Canada Inc |
| Status | Cancelled Post Market — 22 Jun 2000 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Milbemycin Oxime registered in other markets
10 registrations of the same molecule in 1 national registry outside Canada (first 8 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | Milbemycin Oxime | Zhejiang Hisun Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Hubei Honch Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC |
See every manufacturer of Milbemycin Oxime worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Sentinel Tablets 230/11.5 (DIN 02229548) marketed in Canada?
No. Health Canada lists DIN 02229548 as Cancelled Post Market as of 22 Jun 2000.
Who holds the Canadian licence for this product?
Novartis Animal Health Canada Inc is the company of record in the Health Canada Drug Product Database.
Is Milbemycin Oxime registered outside Canada?
Yes — Nexara Health has matched 10 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02229548, status date 2000-06-22; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02229548, status date 2000-06-22; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02229548, status date 2000-06-22; national medicine registries: FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.